| abstract |
The present disclosure provides methods for treating homocystinuria or elevated homocysteine levels in subjects, including methods of improving cognitive function and ameliorating skeletal fragility, and methods of stratifying patient populations to determine disease progression or severity and/or to determine treatment regimens. In some embodiments, the methods of improving cognitive function in a subject having elevated total plasma homocysteine (tHcy) levels further comprise providing a cognitive or behavioral intervention. |